Liraglutide oral - Biora Therapeutics
Alternative Names: BT-200 - Biora Therapeutics; PGN-OB2Latest Information Update: 28 Jul 2025
At a glance
- Originator Progenity
- Developer Biora Therapeutics
- Class Anti-inflammatories; Antihyperglycaemics; Antiparkinsonians; Antirheumatics; Cardiovascular therapies; Glucagon-like peptides; Obesity therapies
- Mechanism of Action Glucagon-like peptide-1 receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Type 2 diabetes mellitus
Most Recent Events
- 28 Jul 2025 No recent reports of development identified for preclinical development in Type-2-diabetes-mellitus in USA (PO, Capsule)
- 07 Aug 2023 Biora Therapeutics has patent protection and multiple patents pending for its oral delivery platforms worldwide
- 03 Aug 2023 Biora Therapeutics has patent protection for BioJet™ systemic oral delivery platform in USA